Paracetamol Accord (Paracetamol)

Paracetamol exerts its effect by inhibiting cyclooxygenase enzymes, especially COX‑2, within the central nervous system. This inhibition reduces the synthesis of prostaglandins that mediate pain signaling and regulate the hypothalamic temperature set‑point, resulting in analgesia and antipyresis. The drug’s action is primarily central, with minimal peripheral anti‑inflammatory activity at therapeutic doses.

The appropriate dose of Paracetamol Accord is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and renal or hepatic function. Healthcare professionals calculate the dosage and infusion rate according to established guidelines, and the medication is administered intravenously under medical supervision.

The safety of intravenous paracetamol during pregnancy or lactation has not been definitively established, and the product is classified as pregnancy category unknown. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. If used, it should be done only under careful medical guidance.

To place an order, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity of Paracetamol Accord. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and assistance with import documentation.

Compared with non‑steroidal anti‑inflammatory drugs (NSAIDs), intravenous paracetamol offers analgesic and antipyretic benefits without the gastrointestinal or platelet‑inhibiting effects typical of NSAIDs. It also provides a faster onset than oral formulations and can be used when oral intake is contraindicated. However, it lacks the anti‑inflammatory potency of NSAIDs and should be selected based on the patient’s overall risk profile.

Paracetamol Accord should be stored at controlled room temperature, below 25 °C, in its original packaging to protect it from moisture and light. The solution must be kept in a clean, dry environment and inspected for particulate matter before administration. Do not freeze or expose the product to extreme temperatures.

The medication is given as an intravenous infusion, typically diluted in a compatible carrier fluid and administered over a short period as directed by the prescriber. Administration should be performed by qualified healthcare personnel using aseptic technique, and the infusion rate may be adjusted according to the patient’s response and clinical guidelines.

The most critical risks include severe allergic reactions such as anaphylaxis, and hepatotoxicity, especially in cases of overdose or pre‑existing liver disease. Rare but serious skin reactions like Stevens‑Johnson syndrome may also occur. Prompt recognition of these events and immediate medical intervention are essential.

Paracetamol Accord is contraindicated in patients with known hypersensitivity to paracetamol or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment, active liver disease, or those who have experienced severe reactions to other analgesics. Clinicians must evaluate each patient’s medical history before prescribing.